Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Arun Gupta
- Registration Number
- NCT03035838
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Autologous Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2022-11-04
- Target Recruit Count
- 22
- Registration Number
- NCT02780609
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
- Conditions
- Locally Advanced Sarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02732015
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: 5-HT3 antagonist
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT02519842
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
- Conditions
- EmesisNon-small Cell Lung CancerNauseaVomiting
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Ajeet Gajra
- Target Recruit Count
- 150
- Registration Number
- NCT02407600
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
- Conditions
- Hematopoietic/Lymphoid CancerNausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 401
- Registration Number
- NCT02116530
- Locations
- 🇺🇸
Southwest Oncology PC, Durango, Colorado, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Illinois CancerCare Galesburg, Galesburg, Illinois, United States
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 942
- Registration Number
- NCT02106494
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HAL, Pheonix, Arizona, United States
🇺🇸Northern Indiana Research, South Bend, Indiana, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 13
- Registration Number
- NCT01874119
- Locations
- 🇺🇸
Saint Louis University Hospital, Saint Louis, Missouri, United States
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
- Conditions
- CINV
- Interventions
- Drug: PlaceboDrug: APD403 IVDrug: APD403 oral
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT01857232
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Lawrence Einhorn
- Target Recruit Count
- 65
- Registration Number
- NCT01736917
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Siteman Cancer Center, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.